Skip to main content
. 2012 Aug 3;7(8):e42701. doi: 10.1371/journal.pone.0042701

Table 6. Rates of ocular adverse effects of RCTs evaluating bevacizumab for indirect comparison and dose-relationship evaluation.

Study Endophthalmitis (%) Uveitis (%) Retinal detachment (%) Retinal tear (%) Lens damage (traumatic) (%) Vitreous haemorrhage (%)
1.0 mg PDT+T 1.0 mg PDT+T 1.0 mg PDT+T 1.0 mg PDT+T 1.0 mg PDT+T 1.0 mg PDT+T
Sacu et al. 2009 [26] 0.0 0.0 0.0 0.7 1.5 0.0 0.0 0.7 0.0 0.0 1.5 0.0
1.25 mg PDT+B 1.25 mg PDT+B 1.25 mg PDT+B 1.25 mg PDT+B 1.25 mg PDT+B 1.25 mg PDT+B
Costagliola et al. 2010 [27] nr nr nr nr nr nr nr nr nr nr nr nr
1.25 mg UC 1.25 mg UC 1.25 mg UC 1.25 mg UC 1.25 mg UC 1.25 mg UC
ABC trial 2010 [28] 0.0 0.0 3.0 2.0 0.0 2.0 0.0 0.0 0.0 0.0 2.0 0.0

B: Bevacizumab. Nr: Not reported. T: Triamcinolone. UC: Usual care.